Latest Administration News

Endeavour Group confirms a fully franked dividend of AUD 0.012 per share for the six months ending June 2026, offering shareholders a choice of payment in Australian or New Zealand dollars based on their registered bank accounts.

Imricor Medical Systems has reached a crucial milestone as the FDA accepts and closes the manufacturing module of its Premarket Approval submission, advancing its MR-guided electrophysiology devices closer to US market entry.

AdAlta’s partner SHcell has gained regulatory approval to provide the BZDS1901 CAR-T therapy to advanced mesothelioma patients in China’s Hainan Boao Lecheng special access zone, marking a key milestone in real-world data collection and treatment availability.

Nova Minerals has kicked off geotechnical drilling for the West Susitna Access Road after AIDEA approved up to US$25 million in additional funding, aiming to unlock critical mineral development and improve logistics for its Estelle Project and antimony refinery.

Telix Pharmaceuticals has completed enrollment in its pivotal Phase 3 BiPASS trial for prostate cancer imaging and aligned with the FDA on a pathway that could expand U.S. patient access and reimbursement for its 68Ga-PSMA-PET agents.

Yowie Group Limited cut its net loss to US$0.20 million in FY26 despite a 27.1% drop in revenue, driven by cost cuts, loan impairment reversals, and new product launches including the Yowie x NBA series.

Actinogen Medical has locked in full underwriting for nearly 127 million unlisted options, guaranteeing $4.77 million in fresh funding as it approaches pivotal Alzheimer’s trial results due in November.

Computershare delivered solid FY26 results with revenue up 4.6% and management EPS rising 8.6%, supported by growth across core businesses and disciplined cost management. The company increased its final dividend by 29% and outlined CEO pay changes to align with global peers.

Artrya has launched its AI-powered Salix® platform commercially in the US, securing three foundation health systems and raising $80 million to fuel growth. With FDA clearance for its Coronary Plaque module and a pivotal clinical study underway, the company is poised for scaling revenues amid a strong balance sheet.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

Pengana International Equities (ASX: PIA) posted a sharp 82% plunge in net profit for FY26, triggering a strategic board reshuffle and a capital management package including a special dividend and buy-back proposal.

Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.